TITLE:
LKB1, A New Biomarker in Breast Cancer
AUTHORS:
Hanine Lattouf, Coralie Poulard, Isabelle Treilleux, Nader Hussein, Mona Diab-Assaf, Muriel Le Romancer
KEYWORDS:
LKB1, Biomarker, Breast Cancer, Estrogen Signaling
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.7 No.10,
September
28,
2016
ABSTRACT: Breast
cancer is the most common cancer in women worldwide. Estrogen signaling
pathways have been identified as efficient targets of breast cancer therapy,
given their key role in promoting breast tumor growth. Agents blocking
estrogen-mediated pathways are routinely used in clinical applications in
patients displaying estrogen-sensitive breast cancer subtypes; however
intrinsic or acquired resistance to treatment often occurs or develops, thus
limiting their efficacy. This
limitation has highlighted an
imperative need to identify new predictive biomarkers. Recent findings
have highlighted a role for the Liver Kinase B1 (LKB1) in breast cancer tumorigenesis.
LKB1 is a serine/threonine kinase mutated in Peutz-Jeghers syndrome (PJS), implicated
in many cellular processes including energy metabolism, cell polarization and
cell cycle arrest and has also been shown to play an essential role as a tumor
suppressor gene by negatively regulating the mTOR pathway. This
review provides an overview of previous findings and ongoing research on LKB1, and substantiates the use
of this kinase as a potential prognostic
and predictive biomarker of breast cancer.